ScripsAmerica, Inc (SCRCQ) Fair Value & Analysis
Healthcare · US · Market cap $14.1K
ScripsAmerica, Inc
SCRCQ · US
Fair value as of: Jun 26, 2026
From 7 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0500 to $0.0001 (−99.8%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.0001 · the $0.0001 price screens below the $0.0001 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ScripsAmerica, Inc (SCRCQ) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 48/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, ScripsAmerica, Inc generated revenue of $39.5M at a net margin of -13.1%. Fundamentals as of Jun 26, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
ScripsAmerica, Inc. is in the process of liquidation of its remaining assets. Previously, the company was engaged in the pharmacy dispensing services for individual doctors, as well as billing and administrative services to independent pharmacies; and distributes pharmaceutical products to independent pharmacies and other medical providers. The company is based in Clifton, New Jersey. On February 8, 2017, the voluntary petition of ScripsAmerica, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 7, 2016.
Revenue & earnings trend
FY2010 – FY2014 · reported fiscal years
ScripsAmerica, Inc reported revenue of $30.9M in FY2014 versus $3.2M in FY2010, a compound +75.9%/yr. Reported net income was −$4.7M in FY2014.
Is SCRCQ fairly valued? → Check now
Similar stocks
6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIY | $5.33 | $7.09 | +33% |
| Alibaba Health Information Technology Limited ALBBY | $8.56 | $6.91 | -19% |
| Raia Drogasil S.A RADL3 | R$17.46 | R$16.13 | -8% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.91 | ¥22.00 | +5% |
| Clicks Group CLCGY | $29.02 | $34.57 | +19% |
| Sugi Holdings SGIPF | $16.29 | $64.34 | +295% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ScripsAmerica, Inc (SCRCQ) undervalued?
What is the fair value of SCRCQ?
What is the quality score of SCRCQ?
What is the revenue of ScripsAmerica, Inc (SCRCQ)?
What is the net profit margin of SCRCQ?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.